Skip to main content
SpringerLink
Log in

The Ras Signalling Pathway as a Target in Cancer Therapy

  • Chapter
Targeted Interference with Signal Transduction Events

Part of the book series: Resent Results in Cancer Research ((RECENTCANCER,volume 172))

Abstract

The Ras GTPase proteins and their down-stream effectors regulate specific intracellular signalling pathways involved in numerous biological processes. Their actions directly influence progression through the cell cycle and the delicate balance of pro- and anti-apoptotic factors. The variety of functions controlled by Ras, and the emerging evidence indicating that aberrations in Ras as well as at multiple points in downstream signalling pathways contribute to tumourigenesis, suggest that Ras signal transduction mechanisms have significant potential as anti-cancer therapeutic targets.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 159.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  • Adjei AA, Dy GK, Erlichman C, Reid JM, Sloan JA, Pitot HC, Alberts SR, Goldberg RM, Hanson LJ, Atherton PJ, Watanabe T, Geary RS, Holmlund J, Dorr FA (2003) A phase I trial of ISIS 2503, an antisense inhibitor of H-ras, in combination with gemcitabine in patients with advanced cancer. Clin Cancer Res 9:115–123

    PubMed  CAS  Google Scholar 

  • Ahmad T, Marais R, Pyle L, James M, Schwartz B, Gore M, Eisen T (2004) BAY 43-9006 in patients with advanced melanoma: The Royal Marsden experience. J Clin Oncol (Meeting Abstracts) 22:7506

    Google Scholar 

  • Ahmadian MR, Zor T, Vogt D, Kabsch W, Selinger Z, Wittinghofer A, Scheffzek K (1999) Guanosine triphosphatase stimulation of oncogenic Ras mutants. Proc Natl Acad Sci USA 96:7065–7070

    Article  PubMed  CAS  Google Scholar 

  • Ahn NG, Nahreini TS, Tolwinski NS, Resing KA (2001) Pharmacologic inhibitors of MKK1 and MKK2. Methods Enzymol 332:417–431

    Article  PubMed  CAS  Google Scholar 

  • Alberts SR, Schroeder M, Erlichman C, Steen PD, Foster NR, Moore DF, Jr, Rowland KM, Jr, Nair S, Tschetter LK, Fitch TR (2004) Gemcitabine and ISIS-2503 for patients with locally advanced or metastatic pancreatic adenocarcinoma: A North Central Cancer Treatment Group Phase II Trial. J Clin Oncol 22:4944–4950

    Article  PubMed  CAS  Google Scholar 

  • Altomare DA, Testa JR (2005) Perturbations of the AKT signaling pathway in human cancer. Oncogene 24:7455–7464

    Article  PubMed  CAS  Google Scholar 

  • Anwar S, Frayling IM, Scott NA, Carlson GL (2004) Systematic review of genetic influences on the prognosis of colorectal cancer. Br J Surg 91:1275–1291

    Article  PubMed  CAS  Google Scholar 

  • Appels NMGM, Beijnen JH, Schellens JHM (2005) Development of farnesyl transferase inhibitors: A review. Oncologist 10:565–578

    Article  PubMed  Google Scholar 

  • Arboleda MJ, Lyons JF, Kabbinavar FF, Bray MR, Snow BE, Ayala R, Danino M, Karlan BY, Slamon DJ (2003) Overexpression of AKT2/protein kinase Bbeta leads to up-regulation of beta1 integrins, increased invasion, and metastasis of human breast and ovarian cancer cells. Cancer Res 63:196–206

    PubMed  CAS  Google Scholar 

  • Ashar HR, James L, Gray K, Carr D, Black S, Armstrong L, Bishop WR, Kirschmeier P (2000) Farnesyl transferase inhibitors block the farnesylation of CENP-E and CENP-F and alter the association of CENP-E with the microtubules. J Biol Chem 275:30451–30457

    Article  PubMed  CAS  Google Scholar 

  • Atkins MB, Hidalgo M, Stadler WM, Logan TF, Dutcher JP, Hudes GR, Park Y, Liou S-H, Marshall B, Boni JP, Dukart G, Sherman ML (2004) Randomized Phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J Clin Oncol 22:909–918

    Article  PubMed  CAS  Google Scholar 

  • Basso AD, Solit DB, Chiosis G, Giri B, Tsichlis P, Rosen N (2002) Akt forms an intracellular complex with heat shock protein 90 (Hsp90) and Cdc37 and is destabilized by inhibitors of Hsp90 function. J Biol Chem 277:39858–39866

    Article  PubMed  CAS  Google Scholar 

  • Beliakoff J, Bagatell R, Paine-Murrieta G, Taylor CW, Lykkesfeldt AE, Whitesell L (2003) Hormone-refractory breast cancer remains sensitive to the antitumor activity of heat shock protein 90 inhibitors. Clin Cancer Res 9:4961–4971

    PubMed  CAS  Google Scholar 

  • Bellacosa A, de Feo D, Godwin AK, Bell DW, Cheng JQ, Altomare DA, Wan M, Dubeau L, Scambia G, Masciullo V, et al. (1995) Molecular alterations of the AKT2 oncogene in ovarian and breast carcinomas. Int J Cancer 64:280–285

    Article  PubMed  CAS  Google Scholar 

  • Bergo MO, Leung GK, Ambroziak P, Otto JC, Casey PJ, Young SG (2000) Targeted inactivation of the isoprenylcysteine carboxyl methyltransferase gene causes mislocalization of K-Ras in mammalian cells. J Biol Chem 275:17605–17610

    Article  PubMed  CAS  Google Scholar 

  • Bergo MO, Leung GK, Ambroziak P, Otto JC, Casey PJ, Gomes AQ, Seabra MC, Young SG (2001) Isoprenylcysteine carboxyl methyltransferase deficiency in mice. J Biol Chem 276:5841–5845

    Article  PubMed  CAS  Google Scholar 

  • Bergo MO, Ambroziak P, Gregory C, George A, Otto JC, Kim E, Nagase H, Casey PJ, Balmain A, Young SG (2002) Absence of the CAAX endoprotease Rce1: Effects on cell growth and transformation. Mol Cell Biol 22:171–181

    Article  PubMed  CAS  Google Scholar 

  • Bergo MO, Gavino BJ, Hong C, Beigneux AP, McMahon M, Casey PJ, Young SG (2004a) Inactivation of ICMT inhibits transformation by oncogenic K-Ras and B-Raf. J Clin Invest 113:539–550

    Article  PubMed  CAS  Google Scholar 

  • Bergo MO, Lieu HD, Gavino BJ, Ambroziak P, Otto JC, Casey PJ, Walker QM, Young SG (2004b) On the physiological importance of endoproteolysis of CAAX Proteins: Heart-specific Rce1 knockout mice develop a lethal cardiomyopathy. J Biol Chem 279:4729–4736

    Article  PubMed  CAS  Google Scholar 

  • Bernhard EJ, Kao G, Cox AD, Sebti SM, Hamilton AD, Muschel RJ, McKenna WG (1996) The farnesyltransferase inhibitor FTI-277 radiosensitizes H-ras-transformed rat embryo fibroblasts. Cancer Res 56:1727–1730

    PubMed  CAS  Google Scholar 

  • Bernhard EJ, McKenna WG, Hamilton AD, Sebti SM, Qian Y, Wu JM, Muschel RJ (1998) Inhibiting Ras prenylation increases the radiosensitivity of human tumor cell lines with activating mutations of ras oncogenes. Cancer Res 58:1754–1761

    PubMed  CAS  Google Scholar 

  • Bernhard EJ, Stanbridge EJ, Gupta S, Gupta AK, Soto D, Bakanauskas VJ, Cerniglia GJ, Muschel RJ, McKenna WG (2000) Direct evidence for the contribution of activated N-ras and K-ras oncogenes to increased intrinsic radiation resistance in human tumor cell lines. Cancer Res 60:6597–6600

    PubMed  CAS  Google Scholar 

  • Bisht KS, Bradbury CM, Mattson D, Kaushal A, Sowers A, Markovina S, Ortiz KL, Sieck LK, Isaacs JS, Brechbiel MW, Mitchell JB, Neckers LM, Gius D (2003) Geldanamycin and 17-allylamino-17-demethoxygeldanamycin potentiate the in vitro and in vivo radiation response of cervical tumor cells via the heat shock protein 90-mediated intracellular signaling and cytotoxicity. Cancer Res 63:8984–8995

    PubMed  CAS  Google Scholar 

  • Bos JL (1989) ras oncogenes in human cancer: a review. Cancer Res 49:4682–4689

    PubMed  CAS  Google Scholar 

  • Brodsky AL, Daley GQ, Hoover RR, Carr D, Kirschmeier P (2003) Apoptotic synergism between STI571 and the farnesyl transferase inhibitor SCH66336 on an imatinib-sensitive cell line. Blood 101:2070

    Article  PubMed  CAS  Google Scholar 

  • Brognard J, Clark AS, Ni Y, Dennis PA (2001) Akt/protein kinase B is constitutively active in non-small cell lung cancer cells and promotes cellular survival and resistance to chemotherapy and radiation. Cancer Res 61:3986–3997

    PubMed  CAS  Google Scholar 

  • Busca R, Bertolotto C, Ortonne J-P, Ballotti R (1996) Inhibition of the phosphatidylinositol 3-kinase/p70S6-kinase pathway induces B16 melanoma cell differentiation. J Biol Chem 271:31824–31830

    Article  PubMed  CAS  Google Scholar 

  • Chan S, Scheulen ME, Johnston S, Mross K, Cardoso F, Dittrich C, Eiermann W, Hess D, Morant R, Semiglazov V, Borner M, Salzberg M, Ostapenko V, Illiger H-J, Behringer D, Bardy-Bouxin N, Boni J, Kong S, Cincotta M, Moore L (2005) Phase II study of temsirolimus (CCI-779), a novel inhibitor of mTOR, in heavily pretreated patients with locally advanced or metastatic breast cancer. J Clin Oncol 23:5314–5322

    Article  PubMed  CAS  Google Scholar 

  • Chardin P, Tavitian A (1986) The ral gene: a new ras related gene isolated by the use of a synthetic probe. EMBO J 5:2203–2208

    PubMed  CAS  Google Scholar 

  • Chen G, Oh S, Monia BP, Stacey DW (1996) Antisense oligonucleotides demonstrate a dominant role of c-Ki-RAS proteins in regulating the proliferation of diploid human fibroblasts. J Biol Chem 271:28259–28265

    Article  PubMed  CAS  Google Scholar 

  • Cheng JQ, Altomare DA, Klein MA, Lee WC, Kruh GD, Lissy NA, Testa JR (1997) Transforming activity and mitosis-related expression of the AKT2 oncogene: evidence suggesting a link between cell cycle regulation and oncogenesis. Oncogene 14:2793–2801

    Article  PubMed  CAS  Google Scholar 

  • Cho H, Mu J, Kim JK, Thorvaldsen JL, Chu Q, Crenshaw EB, 3rd, Kaestner KH, Bartolomei MS, Shulman GI, Birnbaum MJ (2001) Insulin resistance and a diabetes mellitus-like syndrome in mice lacking the protein kinase Akt2 (PKB beta). Science 292:1728–1731

    Article  PubMed  CAS  Google Scholar 

  • Clark GJ, Kinch MS, Rogers-Graham K, Sebti SM, Hamilton AD, Der CJ (1997) The Ras-related protein Rheb is farnesylated and antagonizes ras signaling and transformation. J Biol Chem 272:10608–10615

    Article  PubMed  CAS  Google Scholar 

  • Cloughesy TF, Kuhn J, Robins HI, Abrey L, Wen P, Fink K, Lieberman FS, Mehta M, Chang S, Yung A, DeAngelis L, Schiff D, Junck L, Groves M, Paquette S, Wright J, Lamborn K, Sebti SM, Prados M (2005) Phase I trial of tipifarnib in patients with recurrent malignant glioma taking enzyme-inducing antiepileptic drugs: A North American Brain Tumor Consortium Study. J Clin Oncol 23:6647–6656

    Article  PubMed  CAS  Google Scholar 

  • Cohen-Jonathan E, Toulas C, Ader I, Monteil S, Allal C, Bonnet J, Hamilton AD, Sebti SM, Daly-Schveitzer N, Favre G (1999) The farnesyltransferase inhibitor FTI-277 suppresses the 24-kDa FGF2-induced radioresistance in HeLa cells expressing wild-type RAS. Radiat Res 152:404–411

    Article  PubMed  CAS  Google Scholar 

  • Cohen-Jonathan E, Muschel RJ, Gillies McKenna W, Evans SM, Cerniglia G, Mick R, Kusewitt D, Sebti SM, Hamilton AD, Oliff A, Kohl N, Gibbs JB, Bernhard EJ (2000) Farnesyltransferase inhibitors potentiate the antitumor effect of radiation on a human tumor xenograft expressing activated HRAS. Radiat Res 154:125–132

    Article  PubMed  CAS  Google Scholar 

  • Cortes J (2003) Farnesyltransferase inhibitors in acute myeloid leukemia and myelodysplastic syndromes. Clin Lymphoma 4Suppl 1:S30–S35

    Article  PubMed  Google Scholar 

  • Coudert B, Anthoney A, Fiedler W, Droz JP, Dieras V, Borner M, Smyth JF, Morant R, de Vries MJ, Roelvink M, Fumoleau P (2001) Phase II trial with ISIS 5132 in patients with small-cell (SCLC) and non-small cell (NSCLC) lung cancer. A European Organization for Research and Treatment of Cancer (EORTC) Early Clinical Studies Group report. Eur J Cancer 37:2194–2198

    Article  PubMed  CAS  Google Scholar 

  • Cox AD, Der CJ (2002) Ras family signaling: therapeutic targeting. Cancer Biol Ther 1:599–606

    PubMed  CAS  Google Scholar 

  • Cripps MC, Figueredo AT, Oza AM, Taylor MJ, Fields AL, Holmlund JT, McIntosh LW, Geary RS, Eisenhauer EA (2002) Phase II Randomized study of ISIS 3521 and ISIS 5132 in patients with locally advanced or metastatic colorectal cancer: A National Cancer Institute of Canada Clinical Trials Group Study. Clin Cancer Res 8:2188–2192

    PubMed  CAS  Google Scholar 

  • Crul M, Rosing H, de Klerk GJ, Dubbelman R, Traiser M, Reichert S, Knebel NG, Schellens JHM, Beijnen JH, ten Bokkel Huinink WW (2002) Phase I and pharmacological study of daily oral administration of perifosine (D-21266) in patients with advanced solid tumours. Eur J Cancer 38:1615–1621

    Article  PubMed  CAS  Google Scholar 

  • Cunningham CC, Holmlund JT, Geary RS, Kwoh TJ, Dorr A, Johnston JF, Monia B, Nemunaitis J (2001) A Phase I trial of H-ras antisense oligonucleotide ISIS 2503 administered as a continuous intravenous infusion in patients with advanced carcinoma. Cancer 92:1265–1271

    Article  PubMed  CAS  Google Scholar 

  • da Rocha Dias S, Friedlos F, Light Y, Springer C, Workman P, Marais R (2005) Activated B-RAF Is an Hsp90 client protein that is targeted by the anticancer drug 17-allylamino-17-demethoxygeldanamycin. Cancer Res 65:10686–10691

    Article  PubMed  CAS  Google Scholar 

  • Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, Teague J, Woffendin H, Garnett MJ, Bottomley W, Davis N, Dicks E, Ewing R, Floyd Y, Gray K, Hall S, Hawes R, Hughes J, Kosmidou V, Menzies A, Mould C, Parker A, Stevens C, Watt S, Hooper S, Wilson R, Jayatilake H, Gusterson BA, Cooper C, Shipley J, Hargrave D, Pritchard-Jones K, Maitland N, Chenevix-Trench G, Riggins GJ, Bigner DD, Palmieri G, Cossu A, Flanagan A, Nicholson A, Ho JWC, Leung SY, Yuen ST, Weber BL, Seigler HF, Darrow TL, Paterson H, Marais R, Marshall CJ, Wooster R, Stratton MR, Futreal PA (2002) Mutations of the BRAF gene in human cancer. Nature 417:949–954

    Article  PubMed  CAS  Google Scholar 

  • Delmas C, Heliez C, Cohen-Jonathan E, End D, Bonnet J, Favre G, Toulas C (2002) Farnesyltransferase inhibitor, R115777, reverses the resistance of human glioma cell lines to ionizing radiation. Int J Cancer 100:43–48

    Article  PubMed  CAS  Google Scholar 

  • Demierre M-F, Higgins PDR, Gruber SB, Hawk E, Lippman SM (2005) Statins and cancer prevention. Nat Rev Cancer 5:930–942

    Article  PubMed  CAS  Google Scholar 

  • Diel IJ, Solomayer EF, Bastert G (2000) Bisphosphonates and the prevention of metastasis: first evidences from preclinical and clinical studies. Cancer 88:3080–3088

    Article  PubMed  CAS  Google Scholar 

  • Dolence EK, Dolence JM, Poulter CD (2000) Solid-phase synthesis of a farnesylated CaaX peptide library: inhibitors of the Ras CaaX endoprotease. J Comb Chem 2:522–536

    Article  PubMed  CAS  Google Scholar 

  • Du W, Lebowitz PF, Prendergast GC (1999) Cell growth inhibition by farnesyltransferase inhibitors is mediated by gain of geranylgeranylated RhoB. Mol Cell Biol 19:1831–1840

    PubMed  CAS  Google Scholar 

  • Dudkin L, Dilling MB, Cheshire PJ, Harwood FC, Hollingshead M, Arbuck SG, Travis R, Sausville EA, Houghton PJ (2001) Biochemical correlates of mTOR inhibition by the rapamycin ester CCI-779 and tumor growth inhibition. Clin Cancer Res 7:1758–1764

    PubMed  CAS  Google Scholar 

  • Ellis CA, Vos MD, Wickline M, Riley C, Vallecorsa T, Telford WG, Zujewskil J, Clark GJ (2003) Tamoxifen and the farnesyl transferase inhibitor FTI-277 synergize to inhibit growth in estrogen receptor-positive breast tumor cell lines. Breast Cancer Res Treat 78:59–67

    Article  PubMed  CAS  Google Scholar 

  • Emuss V, Garnett M, Mason C, The Cancer Genome Project, Marais R (2005) Mutations of C-RAF are rare in human cancer because C-RAF has a low basal kinase activity compared with B-RAF. Cancer Res 65:9719–9726

    Article  PubMed  CAS  Google Scholar 

  • End DW, Smets G, Todd AV, Applegate TL, Fuery CJ, Angibaud P, Venet M, Sanz G, Poignet H, Skrzat S, Devine A, Wouters W, Bowden C (2001) Characterization of the antitumor effects of the selective protein farnesyl transferase inhibitor R115777 in vivo and in vitro. Cancer Res 61:131–137

    PubMed  CAS  Google Scholar 

  • Eng C (2003) PTEN: one gene, many syndromes. Hum Mutat 22:183–198

    Article  PubMed  CAS  Google Scholar 

  • Enmon R, Yang WH, Ballangrud AM, Solit DB, Heller G, Rosen N, Scher HI, Sgouros G (2003) Combination treatment with 17-N-allylamino-17-demethoxy geldanamycin and acute irradiation produces supraadditive growth suppression in human prostate carcinoma spheroids. Cancer Res 63:8393–8399

    PubMed  CAS  Google Scholar 

  • Escudier B, Szczylik C, Eisen T, Oudard S, Stadler WM, Schwartz B, Shan M, Bukowski RM (2005a) Randomized Phase III trial of the multi-kinase inhibitor sorafenib (BAY 43-9006) in patients with advanced renal cell carcinoma (RCC). Eur J Cancer 3(S):226

    Google Scholar 

  • Escudier B, Szczylik C, Eisen T, Stadler WM, Schwartz B, Shan M, Bukowski RM (2005b) Randomized phase III trial of the Raf kinase and VEGFR inhibitor sorafenib (BAY 43-9006) in patients with advanced renal cell carcinoma (RCC). J Clin Oncol (Meeting Abstracts) 23:LBA4510

    Google Scholar 

  • Farnsworth C, Seabra M, Ericsson L, Gelb M, Glomset J (1994) Rab geranylgeranyl transferase catalyzes the geranylgeranylation of adjacent cysteines in the small GTPases Rab1A, Rab3A, and Rab5A. Proc Natl Acad Sci USA 91:11963–11967

    Article  PubMed  CAS  Google Scholar 

  • Feig LA (2003) Ral-GTPases: approaching their 15 minutes of fame. Trends Cell Biol 13:419–425

    Article  PubMed  CAS  Google Scholar 

  • Ferrarini M, Heltai S, Zocchi MR, Rugarli C (1992) Unusual expression and localization of heat-shock proteins in human tumor cells. Int J Cancer 51:613–619

    Article  PubMed  CAS  Google Scholar 

  • Flaherty KT, Brose M, Schuchter L, Tuveson D, Lee R, Schwartz B, Lathia C, Weber B, O’Dwyer P (2004) Phase I/II trial of BAY 43-9006, carboplatin (C) and paclitaxel (P) demonstrates preliminary antitumor activity in the expansion cohort of patients with metastatic melanoma. J Clin Oncol (Meeting Abstracts) 22:7507

    Google Scholar 

  • Frost P, Moatamed F, Hoang B, Shi Y, Gera J, Yan H, Frost P, Gibbons J, Lichtenstein A (2004) In vivo antitumor effects of the mTOR inhibitor CCI-779 against human multiple myeloma cells in a xenograft model. Blood 104:4181–4187

    Article  PubMed  CAS  Google Scholar 

  • Gao Y, Dickerson JB, Guo F, Zheng J, Zheng Y (2004) Rational design and characterization of a Rac GTPase-specific small molecule inhibitor. Proc Natl Acad Sci USA 101:7618–7623

    Article  PubMed  CAS  Google Scholar 

  • Geoerger B, Kerr K, Tang C-B, Fung K-M, Powell B, Sutton LN, Phillips PC, Janss AJ (2001) Antitumor activity of the rapamycin analog CCI-779 in human primitive neuroectodermal tumor/medulloblastoma models as single agent and in combination chemotherapy. Cancer Res 61:1527–1532

    PubMed  CAS  Google Scholar 

  • Gokhale PC, McRae D, Monia BP, Bagg A, Rahman A, Dritschilo A, Kasid U (1999) Antisense raf oligodeoxyribonucleotide is a radiosensitizer in vivo. Antisense Nucleic Acid Drug Dev 9:191–201

    PubMed  CAS  Google Scholar 

  • Gonzalez-Garcia A, Pritchard CA, Paterson HF, Mavria G, Stamp G, Marshall CJ (2005) RalGDS is required for tumor formation in a model of skin carcinogenesis. Cancer Cell 7:219–226

    Article  PubMed  CAS  Google Scholar 

  • Graaf MR, Richel DJ, van Noorden CJ, Guchelaar HJ (2004) Effects of statins and farnesyltransferase inhibitors on the development and progression of cancer. Cancer Treat Rev 30:609–641

    Article  PubMed  CAS  Google Scholar 

  • Grbovic OM, Basso AD, Sawai A, Ye Q, Friedlander P, Solit D, Rosen N (2006) V600E B-Raf requires the Hsp90 chaperone for stability and is degraded in response to Hsp90 inhibitors. Proc Natl Acad Sci USA 103:57–62

    Article  PubMed  CAS  Google Scholar 

  • Hahn SM, Bernhard EJ, Regine W, Mohiuddin M, Haller DG, Stevenson JP, Smith D, Pramanik B, Tepper J, DeLaney TF, Kiel KD, Morrison B, Deutsch P, Muschel RJ, McKenna WG (2002) A Phase I trial of the farne-syltransferase inhibitor L-778,123 and radiotherapy for locally advanced lung and head and neck cancer. Clin Cancer Res 8:1065–1072

    PubMed  CAS  Google Scholar 

  • Hancock JF, Magee AI, Childs JE, Marshall CJ (1989) All ras proteins are polyisoprenylated but only some are palmitoylated. Cell 57:1167–1177

    Article  PubMed  CAS  Google Scholar 

  • Hilgard P, Klenner T, Stekar J, Nossner G, Kutscher B, Engel J (1997) D-21266, a new heterocyclic alkylphospholipid with antitumour activity. Eur J Cancer 33:442–446

    Article  PubMed  CAS  Google Scholar 

  • Hingorani SR, Jacobetz MA, Robertson GP, Herlyn M, Tuveson DA (2003) Suppression of BRAFV599E in human melanoma abrogates transformation. Cancer Res 63:5198–5202

    PubMed  CAS  Google Scholar 

  • Holmlund JT, Monia BP, Kwoh TJ, Dorr FA (1999) Toward antisense oligonucleotide therapy for cancer: ISIS compounds in clinical development. Curr Opin Mol Ther 1:372–385

    PubMed  CAS  Google Scholar 

  • Hotte SJ, Hirte HW (2002) BAY 43-9006: early clinical data in patients with advanced solid malignancies. Curr Pharm Des 8:2249–2253

    Article  PubMed  CAS  Google Scholar 

  • Hu L, Zaloudek C, Mills GB, Gray J, Jaffe RB (2000) In vivo and in vitro ovarian carcinoma growth inhibition by a phosphatidylinositol 3-kinase inhibitor (LY294002). Clin Cancer Res 6:880–886

    PubMed  CAS  Google Scholar 

  • Hu L, Hofmann J, Lu Y, Mills GB, Jaffe RB (2002) Inhibition of phosphatidylinositol 3′-kinase increases efficacy of paclitaxel in in vitro and in vivo ovarian cancer models. Cancer Res 62:1087–1092

    PubMed  CAS  Google Scholar 

  • Humar R, Kiefer FN, Berns H, Resink TJ, Battegay EJ (2002) Hypoxia enhances vascular cell proliferation and angiogenesis in vitro via rapamycin (mTOR)-dependent signaling. FASEB J 16:771–780

    Article  PubMed  CAS  Google Scholar 

  • Hussein D, Taylor SS (2002) Farnesylation of Cenp-F is required for G2/M progression and degradation after mitosis. J Cell Sci 115:3403–3414

    PubMed  CAS  Google Scholar 

  • Isakoff SJ, Engelman JA, Irie HY, Luo J, Brachmann SM, Pearline RV, Cantley LC, Brugge JS (2005) Breast cancer-associated PIK3CA mutations are oncogenic in mammary epithelial cells. Cancer Res 65:10992–11000

    Article  PubMed  CAS  Google Scholar 

  • Jackson J, Cochrane C, Bourne J, Solski P, Buss J, Der C (1990) Farnesol modification of Kirsten-Ras exon 4B protein is essential for transformation. Proc Natl Acad Sci USA 87:3042–3046

    Article  PubMed  CAS  Google Scholar 

  • Johnston SRD, Hickish T, Ellis P, Houston S, Kelland L, Dowsett M, Salter J, Michiels B, Perez-Ruixo JJ, Palmer P, Howes A (2003) Phase II study of the efficacy and tolerability of two dosing regimens of the farnesyl transferase inhibitor, R115777, in advanced breast cancer. J Clin Oncol 21:2492–2499

    Article  PubMed  CAS  Google Scholar 

  • Karasarides M, Chiloeches A, Hayward R, Niculescu-Duvaz D, Scanlon I, Friedlos F, Ogilvie L, Hedley D, Martin J, Marshall CJ, Springer CJ, Marais R (2004) B-RAF is a therapeutic target in melanoma. Oncogene 23:6292–6298

    Article  PubMed  CAS  Google Scholar 

  • Karp JE, Kaufmann SH, Adjei AA, Lancet JE, Wright JJ, End DW (2001) Current status of clinical trials of farnesyltransferase inhibitors. Curr Opin Oncol 13:470–476

    Article  PubMed  CAS  Google Scholar 

  • Kato K, Cox A, Hisaka M, Graham S, Buss J, Der C (1992) Isoprenoid addition to Ras protein is the critical modification for its membrane association and transforming activity. Proc Natl Acad Sci USA 89:6403–6407

    Article  PubMed  CAS  Google Scholar 

  • Kim E, Ambroziak P, Otto JC, Taylor B, Ashby M, Shannon K, Casey PJ, Young SG (1999) Disruption of the mouse Rce1 gene results in defective Ras processing and mislocalization of Ras within cells. J Biol Chem 274:8383–8390

    Article  PubMed  CAS  Google Scholar 

  • Kohl NE, Mosser SD, deSolms SJ, Giuliani EA, Pompliano DL, Graham SL, Smith RL, Scolnick EM, Oliff A, Gibbs JB (1993) Selective inhibition of ras-dependent transformation by a farnesyltransferase inhibitor. Science 260:1934–1937

    Article  PubMed  CAS  Google Scholar 

  • Kondapaka SB, Singh SS, Dasmahapatra GP, Sausville EA, Roy KK (2003) Perifosine, a novel alkylphospholipid, inhibits protein kinase B activation. Mol Cancer Ther 2:1093–1103

    PubMed  CAS  Google Scholar 

  • Kramer K, Harrington EO, Lu Q, Bellas R, Newton J, Sheahan KL, Rounds S (2003) Isoprenylcysteine carboxyl methyltransferase activity modulates endothelial cell apoptosis. Mol Biol Cell 14:848–857

    Article  PubMed  CAS  Google Scholar 

  • Kurzrock R, Kantarjian HM, Cortes JE, Singhania N, Thomas DA, Wilson EF, Wright JJ, Freireich EJ, Talpaz M, Sebti SM (2003) Farnesyltransferase inhibitor R115777 in myelodysplastic syndrome: clinical and biologic activities in the phase 1 setting. Blood 102:4527–4534

    Article  PubMed  CAS  Google Scholar 

  • Lebowitz PF, Casey PJ, Prendergast GC, Thissen JA (1997) Farnesyltransferase inhibitors alter the prenylation and growth-stimulating function of RhoB. J Biol Chem 272:15591–15594

    Article  PubMed  CAS  Google Scholar 

  • Ling CC, Endlich B (1989) Radioresistance induced by oncogenic transformation. Radiat Res 120:267–279

    Article  PubMed  CAS  Google Scholar 

  • Liu A-x, Du W, Liu J-P, Jessell TM, Prendergast GC (2000) RhoB alteration is necessary for apoptotic and antineoplastic responses to farnesyltransferase inhibitors. Mol Cell Biol 20:6105–6113

    Article  PubMed  CAS  Google Scholar 

  • Lobell RB, Omer CA, Abrams MT, Bhimnathwala HG, Brucker MJ, Buser CA, Davide JP, deSolms SJ, Dinsmore CJ, Ellis-Hutchings MS, Kral AM, Liu D, Lumma WC, Machotka SV, Rands E, Williams TM, Graham SL, Hartman GD, Oliff AI, Heimbrook DC, Kohl NE (2001) Evaluation of farnesyl: protein transferase and geranylgeranyl: protein transferase inhibitor combinations in preclinical models. Cancer Res 61:8758–8768

    PubMed  CAS  Google Scholar 

  • Luo Y, Shoemaker AR, Liu X, Woods KW, Thomas SA, de Jong R, Han EK, Li T, Stoll VS, Powlas JA, Oleksijew A, Mitten MJ, Shi Y, Guan R, McGonigal TP, Klinghofer V, Johnson EF, Leverson JD, Bouska JJ, Mamo M, Smith RA, Gramling-Evans EE, Zinker BA, Mika AK, Nguyen PT, Oltersdorf T, Rosenberg SH, Li Q, Giranda VL (2005) Potent and selective inhibitors of Akt kinases slow the progress of tumors in vivo. Mol Cancer Ther 4:977–986

    Article  PubMed  CAS  Google Scholar 

  • Lyons J, Wilhelm S, Hibner B, Bollag G (2001) Discovery of a novel Raf kinase inhibitor. Endocr Relat Cancer 8:219–225

    Article  PubMed  CAS  Google Scholar 

  • Mak BC, Yeung RS (2004) The tuberous sclerosis complex genes in tumor development. Cancer Invest 22:588–603

    Article  PubMed  CAS  Google Scholar 

  • Malliri A, van der Kammen RA, Clark K, van der Valk M, Michiels F, Collard JG (2002) Mice deficient in the Rac activator Tiam1 are resistant to Ras-induced skin tumours. Nature 417:867–871

    Article  PubMed  CAS  Google Scholar 

  • Mandler R, Kobayashi H, Hinson ER, Brechbiel MW, Waldmann TA (2004) Herceptin-geldanamycin immunoconjugates: pharmacokinetics, biodistribution, and enhanced antitumor activity. Cancer Res 64:1460–1467

    Article  PubMed  CAS  Google Scholar 

  • Marcus AI, Zhou J, O’Brate A, Hamel E, Wong J, Nivens M, El-Naggar A, Yao T-P, Khuri FR, Giannakakou P (2005) The synergistic combination of the farnesyl transferase inhibitor lonafarnib and paclitaxel enhances tubulin acetylation and requires a functional tubulin deacetylase. Cancer Res 65:3883–3893

    Article  PubMed  CAS  Google Scholar 

  • Martin GA, Viskochil D, Bollag G, McCabe PC, Crosier WJ, Haubruck H, Conroy L, Clark R, O’Connell P, Cawthon RM, et al. (1990) The GAP-related domain of the neurofibromatosis type 1 gene product interacts with ras p21. Cell 63:843–849

    Article  PubMed  CAS  Google Scholar 

  • Martin NE, Brunner TB, Kiel KD, DeLaney TF, Regine WF, Mohiuddin M, Rosato EF, Haller DG, Stevenson JP, Smith D, Pramanik B, Tepper J, Tanaka WK, Morrison B, Deutsch P, Gupta AK, Muschel RJ, McKenna WG, Bernhard EJ, Hahn SM (2004) A Phase I trial of the dual farnesyltransferase and geranylgeranyl-transferase inhibitor L-778,123 and radiotherapy for locally advanced pancreatic cancer. Clin Cancer Res 10:5447–5454

    Article  PubMed  CAS  Google Scholar 

  • Mascaux C, Iannino N, Martin B, Paesmans M, Berghmans T, Dusart M, Haller A, Lothaire P, Meert AP, Noel S, Lafitte JJ, Sculier JP (2005) The role of RAS oncogene in survival of patients with lung cancer: a systematic review of the literature with meta-analysis. Br J Cancer 92:131–139

    Article  PubMed  CAS  Google Scholar 

  • Mason CS, Springer CJ, Cooper RG, Superti-Furga G, Marshall CJ, Marais R (1999) Serine and tyrosine phosphorylations cooperate in Raf-1, but not B-Raf activation. EMBO J 18:2137–2148

    Article  PubMed  CAS  Google Scholar 

  • Mavria G, Vercoulen Y, Yeo M, Paterson H, Karasarides M, Marais R, Bird D, Marshall CJ (2006) ERK-MAPK signaling opposes Rho-kinase to promote endothelial cell survival and sprouting during angiogenesis. Cancer Cell 9:33–44

    Article  PubMed  CAS  Google Scholar 

  • McCoy MS, Bargmann CI, Weinberg RA (1984) Human colon carcinoma Ki-ras2 oncogene and its corresponding proto-oncogene. Mol Cell Biol 4:1577–1582

    PubMed  CAS  Google Scholar 

  • McKenna WG, Weiss MC, Bakanauskas VJ, Sandler H, Kelsten ML, Biaglow J, Tuttle SW, Endlich B, Ling CC, Muschel RJ (1990a) The role of the H-ras oncogene in radiation resistance and metastasis. Int J Radiat Oncol Biol Phys 18:849–859

    PubMed  CAS  Google Scholar 

  • McKenna WG, Weiss MC, Endlich B, Ling CC, Bakanauskas VJ, Kelsten ML, Muschel RJ (1990b) Synergistic effect of the v-myc oncogene with H-ras on radioresistance. Cancer Res 50:97–102

    PubMed  CAS  Google Scholar 

  • Micci F, Teixeira MR, Haugom L, Kristensen G, Abeler VM, Heim S (2004) Genomic aberrations in carcinomas of the uterine corpus. Genes Chromosomes Cancer 40:229–246

    Article  PubMed  CAS  Google Scholar 

  • Michaloglou C, Vredeveld LCW, Soengas MS, Denoyelle C, Kuilman T, van der Horst CMAM, Majoor DM, Shay JW, Mooi WJ, Peeper DS (2005) BRAFE600-associated senescence-like cell cycle arrest of human naevi. Nature 436:720–724

    Article  PubMed  CAS  Google Scholar 

  • Mijimolle N, Velasco J, Dubus P, Guerra C, Weinbaum CA, Casey PJ, Campuzano V, Barbacid M (2005) Protein farnesyltransferase in embryogenesis, adult homeostasis, and tumor development. Cancer Cell 7:313–324

    Article  PubMed  CAS  Google Scholar 

  • Moasser MM, Sepp-Lorenzino L, Kohl NE, Oliff A, Balog A, Su D-S, Danishefsky SJ, Rosen N (1998) Farnesyl transferase inhibitors cause enhanced mitotic sensitivity to taxol and epothilones. Proc Natl Acad Sci USA 95:1369–1374

    Article  PubMed  CAS  Google Scholar 

  • Monia BP, Johnston JF, Ecker DJ, Zounes MA, Lima WF, Freier SM (1992) Selective inhibition of mutant Haras mRNA expression by antisense oligonucleotides. J Biol Chem 267:19954–19962

    PubMed  CAS  Google Scholar 

  • Monia BP, Johnston JF, Geiger T, Muller M, Fabbro D (1996a) Antitumor activity of a phosphorothioate antisense oligodeoxynucleotide targeted against Craf kinase. Nat Med 2:668–675

    Article  PubMed  CAS  Google Scholar 

  • Monia BP, Sasmor H, Johnston JF, Freier SM, Lesnik EA, Muller M, Geiger T, Altmann KH, Moser H, Fabbro D (1996b) Sequence-specific antitumor activity of a phosphorothioate oligodeoxyribonucleotide targeted to human C-raf kinase supports an antisense mechanism of action in vivo. Proc Natl Acad Sci USA 93:15481–15484

    Article  PubMed  CAS  Google Scholar 

  • Morgan MA, Dolp O, Reuter CWM (2001) Cell-cycledependent activation of mitogen-activated protein kinase kinase (MEK-1/2) in myeloid leukemia cell lines and induction of growth inhibition and apoptosis by inhibitors of RAS signaling. Blood 97:1823–1834

    Article  PubMed  CAS  Google Scholar 

  • Munster PN, Basso A, Solit D, Norton L, Rosen N (2001) Modulation of Hsp90 function by ansamycins sensitizes breast cancer cells to chemotherapy-induced apoptosis in an RB-and schedule-dependent manner. Clin Cancer Res 7:2228–2236

    PubMed  CAS  Google Scholar 

  • Nakajima A, Tauchi T, Sumi M, Bishop WR, Ohyashiki K (2003) Efficacy of SCH66336, a farnesyl transferase inhibitor, in conjunction with imatinib against BCRABL-positive cells. Mol Cancer Ther 2:219–224

    PubMed  CAS  Google Scholar 

  • Neckers L, Ivy SP (2003) Heat shock protein 90. Curr Opin Oncol 15:419–424

    Article  PubMed  CAS  Google Scholar 

  • Nicol D, Hii SI, Walsh M, Teh B, Thompson L, Kennett C, Gotley D (1997) Vascular endothelial growth factor expression is increased in renal cell carcinoma. J Urol 157:1482–1486

    Article  PubMed  CAS  Google Scholar 

  • Oza AM, Elit L, Swenerton K, Faught W, Ghatage P, Carey M, McIntosh L, Dorr A, Holmlund JT, Eisenhauer E (2003) Phase II study of CGP 69846A (ISIS 5132) in recurrent epithelial ovarian cancer: an NCIC clinical trials group study (NCIC IND.116)*. Gynecol Oncol 89:129–133

    Article  PubMed  CAS  Google Scholar 

  • Podsypanina K, Ellenson LH, Nemes A, Gu J, Tamura M, Yamada KM, Cordon-Cardo C, Catoretti G, Fisher PE, Parsons R (1999) Mutation of Pten/Mmac1 in mice causes neoplasia in multiple organ systems. Proc Natl Acad Sci USA 96:1563–1568

    Article  PubMed  CAS  Google Scholar 

  • Pollock PM, Harper UL, Hansen KS, Yudt LM, Stark M, Robbins CM, Moses TY, Hostetter G, Wagner U, Kakareka J, Salem G, Pohida T, Heenan P, Duray P, Kallioniemi O, Hayward NK, Trent JM, Meltzer PS (2003) High frequency of BRAF mutations in nevi. Nat Genet 33:19–20

    Article  PubMed  CAS  Google Scholar 

  • Punt CJA, Boni J, Bruntsch U, Peters M, Thielert C (2003) Phase I and pharmacokinetic study of CCI-779, a novel cytostatic cell-cycle inhibitor, in combination with 5-fluorouracil and leucovorin in patients with advanced solid tumors. Ann Oncol 14:931–937

    Article  PubMed  CAS  Google Scholar 

  • Rajagopalan H, Bardelli A, Lengauer C, Kinzler KW, Vogelstein B, Velculescu VE (2002) Tumorigenesis-RAF/RAS oncogenes and mismatch-repair status. Nature 418:934

    Article  PubMed  CAS  Google Scholar 

  • Rao S, Cunningham D, de Gramont A, Scheithauer W, Smakal M, Humblet Y, Kourteva G, Iveson T, Andre T, Dostalova J, Illes A, Belly R, Perez-Ruixo JJ, Park YC, Palmer PA (2004) Phase III double-blind placebo-controlled study of farnesyl transferase inhibitor R115777 in patients with refractory advanced colorectal cancer. J Clin Oncol 22:3950–3957

    Article  PubMed  CAS  Google Scholar 

  • Ratain MJ, Eisen T, Stadler WM, Flaherty KT, Gore M, Desai A, Patnaik A, Xiong HQ, Schwartz B, O’Dwyer P (2005) Final findings from a phase II, placebo-controlled, randomized discontinuation trial (RDT) of sorafenib (BAY 43-9006) in patients with advanced renal cell carcinoma (RCC). J Clin Oncol (Meeting Abstracts) 23:4544

    Google Scholar 

  • Reuter CWM, Morgan MA, Bergmann L (2000) Targeting the Ras signaling pathway: a rational, mechanismbased treatment for hematologic malignancies? Blood 96:1655–1669

    PubMed  CAS  Google Scholar 

  • Rinehart J, Adjei AA, Lorusso PM, Waterhouse D, Hecht JR, Natale RB, Hamid O, Varterasian M, Asbury P, Kaldjian EP, Gulyas S, Mitchell DY, Herrera R, Sebolt-Leopold JS, Meyer MB (2004) Multicenter phase II study of the oral MEK inhibitor, CI-1040, in patients with advanced non-small-cell lung, breast, colon, and pancreatic cancer. J Clin Oncol 22:4456–4462

    Article  PubMed  CAS  Google Scholar 

  • Risinger J, Hayes K, Maxwell G, Carney M, Dodge R, Barrett J, Berchuck A (1998) PTEN mutation in endometrial cancers is associated with favorable clinical and pathologic characteristics. Clin Cancer Res 4:3005–3010

    PubMed  CAS  Google Scholar 

  • Ross PJ, George M, Cunningham D, DiStefano F, Andreyev HJN, Workman P, Clarke PA (2001) Inhibition of Kirsten-ras expression in human colorectal cancer using rationally selected Kirsten-ras antisense oligonucleotides. Mol Cancer Ther 1:29–41

    PubMed  CAS  Google Scholar 

  • Rudin CM, Holmlund J, Fleming GF, Mani S, Stadler WM, Schumm P, Monia BP, Johnston JF, Geary R, Yu RZ, Kwoh TJ, Dorr FA, Ratain MJ (2001) Phase I Trial of ISIS 5132, an antisense oligonucleotide inhibitor of c-raf-1, administered by 24-hour weekly infusion to patients with advanced cancer. Clin Cancer Res 7:1214–1220

    PubMed  CAS  Google Scholar 

  • Samid D, Miller AC, Rimoldi D, Gafner J, Clark EP (1991) Increased radiation resistance in transformed and nontransformed cells with elevated ras proto-oncogene expression. Radiat Res 126:244–250

    Article  PubMed  CAS  Google Scholar 

  • Samuels Y, Wang Z, Bardelli A, Silliman N, Ptak J, Szabo S, Yan H, Gazdar A, Powell SM, Riggins GJ, Willson JK, Markowitz S, Kinzler KW, Vogelstein B, Velculescu VE (2004) High frequency of mutations of the PIK3CA gene in human cancers. Science 304:554

    Article  PubMed  CAS  Google Scholar 

  • Sansal I, Sellers WR (2004) The Biology and Clinical Relevance of the PTEN Tumor Suppressor Pathway. J Clin Oncol 22:2954–2963

    Article  PubMed  CAS  Google Scholar 

  • Sarkaria JN, Tibbetts RS, Busby EC, Kennedy AP, Hill DE, Abraham RT (1998) Inhibition of phosphoinositide 3-kinase related kinases by the radiosensitizing agent wortmannin. Cancer Res 58:4375–4382

    PubMed  CAS  Google Scholar 

  • Schlitzer M, Winter-Vann A, Casey PJ (2001) Non-peptidic, non-prenylic inhibitors of the prenyl proteinspecific protease Rce1. Bioorg Medicinal Chem Lett 11:425–427

    Article  CAS  Google Scholar 

  • Schulte TW, Blagosklonny MV, Romanova L, Mushinski JF, Monia BP, Johnston JF, Nguyen P, Trepel J, Neckers LM (1996) Destabilization of Raf-1 by geldanamycin leads to disruption of the Raf-1-MEK-mitogen-activated protein kinase signalling pathway. Mol Cell Biol 16:5839–5845

    PubMed  CAS  Google Scholar 

  • Schultz RM, Merriman RL, Andis SL, Bonjouklian R, Grindey GB, Rutherford PG, Gallegos A, Massey K, Powis G (1995) In vitro and in vivo antitumor activity of the phosphatidylinositol-3-kinase inhibitor, wortmannin. Anticancer Res 15:1135–1139

    PubMed  CAS  Google Scholar 

  • Sebolt-Leopold JS, Dudley DT, Herrera R, Van Becelaere K, Wiland A, Gowan RC, Tecle H, Barrett SD, Bridges A, Przybranowski S, Leopold WR, Saltiel AR (1999) Blockade of the MAP kinase pathway suppresses growth of colon tumors in vivo. Nat Med 5:810–816

    Article  PubMed  CAS  Google Scholar 

  • Sebti SM, Adjei AA (2004) Farnesyltransferase inhibitors. Semin Oncol 31:28–39

    Article  PubMed  CAS  Google Scholar 

  • Sebti SM, Hamilton AD (2000) Farnesyltransferase and geranylgeranyltransferase I inhibitors and cancer therapy: lessons from mechanism and bench-to-bedside translational studies. Oncogene 19:6584–6593

    Article  PubMed  CAS  Google Scholar 

  • Senaratne SG, Pirianov G, Mansi JL, Arnett TR, Colston KW (2000) Bisphosphonates induce apoptosis in human breast cancer cell lines. Br J Cancer 82:1459–1468

    PubMed  CAS  Google Scholar 

  • Shayesteh L, Lu Y, Kuo WL, Baldocchi R, Godfrey T, Collins C, Pinkel D, Powell B, Mills GB, Gray JW (1999) PIK3CA is implicated as an oncogene in ovarian cancer. Nat Genet 21:99–102

    Article  PubMed  CAS  Google Scholar 

  • Shi Y, Gera J, Liping H, Jung-hsin H, Bookstein R, Weiqun L, Lichenstein A (2002) Enhanced sensitivity of multiple myeloma cells to CCI-779. Cancer Res 62:5027–5034

    PubMed  CAS  Google Scholar 

  • Singer G, Oldt R, III, Cohen Y, Wang BG, Sidransky D, Kurman RJ, Shih I-M (2003) Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma. J Natl Cancer Inst 95:484–486

    Article  PubMed  CAS  Google Scholar 

  • Smith JS, Tachibana I, Passe SM, Huntley BK, Borell TJ, Iturria N, O’Fallon JR, Schaefer PL, Scheithauer BW, James CD, Buckner JC, Jenkins RB (2001) PTEN mutation, EGFR amplification, and outcome in patients with anaplastic astrocytoma and glioblastoma multiforme. J Natl Cancer Inst 93:1246–1256

    Article  PubMed  CAS  Google Scholar 

  • Smith JW, Ko Y-J, Dutcher J, Hudes G, Escudier B, Motzer R, Negrier S, Duclos B, Galand L, Strauss L (2004) Update of a phase 1 study of intravenous CCI-779 given in combination with interferon-alpha to patients with advanced renal cell carcinoma. J Clin Oncol (Meeting Abstracts) 22:4513

    Google Scholar 

  • Solit DB, Zheng FF, Drobnjak M, Munster PN, Higgins B, Verbel D, Heller G, Tong W, Cordon-Cardo C, Agus DB, Scher HI, Rosen N (2002) 17-Allylamino-17-demethoxygeldanamycin induces the degradation of androgen receptor and HER-2/neu and inhibits the growth of prostate cancer xenografts. Clin Cancer Res 8:986–993

    PubMed  CAS  Google Scholar 

  • Solit DB, Garraway LA, Pratilas CA, Sawai A, Getz G, Basso A, Ye Q, Lobo JM, She Y, Osman I, Golub TR, Sebolt-Leopold J, Sellers WR, Rosen N (2006) BRAF mutation predicts sensitivity to MEK inhibition. Nature 439:358–362

    Article  PubMed  CAS  Google Scholar 

  • Sprang S (1997) G protein mechanisms: insights from structural analysis. Annu Rev Biochem 66:639–678

    Article  PubMed  CAS  Google Scholar 

  • Stambolic V, Tsao M-S, Macpherson D, Suzuki A, Chapman WB, Mak TW (2000) High incidence of breast and endometrial neoplasia resembling human Cowden syndrome in pten+/-mice. Cancer Res 60:3605–3611

    PubMed  CAS  Google Scholar 

  • Sun J, Blaskovich MA, Knowles D, Qian Y, Ohkanda J, Bailey RD, Hamilton AD, Sebti SM (1999) Antitumor efficacy of a novel class of non-thiol-containing peptidomimetic inhibitors of farnesyltransferase and geranylgeranyltransferase I: combination therapy with the cytotoxic agents cisplatin, Taxol, and gemcitabine. Cancer Res 59:4919–4926

    PubMed  CAS  Google Scholar 

  • Sun M, Wang G, Paciga JE, Feldman RI, Yuan ZQ, Ma XL, Shelley SA, Jove R, Tsichlis PN, Nicosia SV, Cheng JQ (2001) AKT1/PKBalpha kinase is frequently elevated in human cancers and its constitutive activation is required for oncogenic transformation in NIH3T3 cells. Am J Pathol 159:431–437

    PubMed  CAS  Google Scholar 

  • Tassone P, Forciniti S, Galea E, Morrone G, Turco MC, Martinelli V, Tagliaferri P, Venuta S (2000) Growth inhibition and synergistic induction of apoptosis by zoledronate and dexamethasone in human myeloma cell lines. Leukemia 14:841–844

    Article  PubMed  CAS  Google Scholar 

  • Tolcher AW, Reyno L, Venner PM, Ernst SD, Moore M, Geary RS, Chi K, Hall S, Walsh W, Dorr A, Eisenhauer E (2002) A randomized Phase II and pharmacokinetic study of the antisense oligonucleotides ISIS 3521 and ISIS 5132 in patients with hormone-refractory prostate cancer. Clin Cancer Res 8:2530–2535

    PubMed  CAS  Google Scholar 

  • Van Cutsem E, van de Velde H, Karasek P, Oettle H, Vervenne WL, Szawlowski A, Schoffski P, Post S, Verslype C, Neumann H, Safran H, Humblet Y, Perez Ruixo J, Ma Y, Von Hoff D (2004) Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer. J Clin Oncol 22:1430–1438

    Article  PubMed  CAS  Google Scholar 

  • Van Ummersen L, Binger K, Volkman J, Marnocha R, Tutsch K, Kolesar J, Arzoomanian R, Alberti D, Wilding G (2004) A Phase I trial of perifosine (NSC 639966) on a loading dose/maintenance dose schedule in patients with advanced cancer. Clin Cancer Res 10:7450–7456

    Article  PubMed  Google Scholar 

  • Vincenzi B, Santini D, Avvisati G, Baldi A, Cesa AL, Tonini G (2003) Statins may potentiate bisphosphonates anticancer properties: a new pharmacological approach? Med Hypotheses 61:98–101

    Article  PubMed  CAS  Google Scholar 

  • Vivanco I, Sawyers CL (2002) The phosphatidylinositol 3-kinase AKT pathway in human cancer. Nat Rev Cancer 2:489–501

    Article  PubMed  CAS  Google Scholar 

  • Wallace EM, Lyssikatos JP, Yeh T, Winkler JD, Koch K (2005) Progress towards therapeutic small molecule MEK inhibitors for use in cancer therapy. Curr Top Med Chem 5:215–229

    Article  PubMed  CAS  Google Scholar 

  • Wan PT, Garnett MJ, Roe SM, Lee S, Niculescu-Duvaz D, Good VM, Jones CM, Marshall CJ, Springer CJ, Barford D, Marais R (2004) Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell 116:855–867

    Article  PubMed  CAS  Google Scholar 

  • West KA, Sianna Castillo S, Dennis PA (2002) Activation of the PI3K/Akt pathway and chemotherapeutic resistance. Drug Resistance Updates 5:234–248

    Article  PubMed  CAS  Google Scholar 

  • Whitesell L, Lindquist SL (2005) Hsp90 and the chaperoning of cancer. Nat Rev Cancer 5:761–772

    Article  PubMed  CAS  Google Scholar 

  • Whitesell L, Mimnaugh EG, De Costa B, Myers CE, Neckers LM (1994) Inhibition of heat shock protein HSP90-pp60v-src heteroprotein complex formation by benzoquinone ansamycins: essential role for stress proteins in oncogenic transformation. Proc Natl Acad Sci USA 91:8324–8328

    Article  PubMed  CAS  Google Scholar 

  • Whyte DB, Kirschmeier P, Hockenberry TN, Nunez-Oliva I, James L, Catino JJ, Bishop WR, Pai J-K (1997) K-and N-Ras are geranylgeranylated in cells treated with farnesyl protein transferase inhibitors. J Biol Chem 272:14459–14464

    Article  PubMed  CAS  Google Scholar 

  • Wilhelm SM, Carter C, Tang L, Wilkie D, McNabola A, Rong H, Chen C, Zhang X, Vincent P, McHugh M, Cao Y, Shujath J, Gawlak S, Eveleigh D, Rowley B, Liu L, Adnane L, Lynch M, Auclair D, Taylor I, Gedrich R, Voznesensky A, Riedl B, Post LE, Bollag G, Trail PA (2004) BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 64:7099–7109

    Article  PubMed  CAS  Google Scholar 

  • Xu GF, Lin B, Tanaka K, Dunn D, Wood D, Gesteland R, White R, Weiss R, Tamanoi F (1990a) The catalytic domain of the neurofibromatosis type 1 gene product stimulates ras GTPase and complements ira mutants of S. cerevisiae. Cell 63:835–841

    CAS  Google Scholar 

  • Xu GF, O’Connell P, Viskochil D, Cawthon R, Robertson M, Culver M, Dunn D, Stevens J, Gesteland R, White R, et al. (1990b) The neurofibromatosis type 1 gene encodes a protein related to GAP. Cell 62:599–608

    Article  PubMed  CAS  Google Scholar 

  • Yang JC, Haworth L, Sherry RM, Hwu P, Schwartzentruber DJ, Topalian SL, Steinberg SM, Chen HX, Rosenberg SA (2003) A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 349:427–434

    Article  PubMed  CAS  Google Scholar 

  • Yano M, Naito Z, Tanaka S, Asano G (1996) Expression and roles of heat shock proteins in human breast cancer. Jpn J Cancer Res 87:908–915

    PubMed  CAS  Google Scholar 

  • Zaal LH, Mooi WJ, Sillevis Smitt JH, van der Horst CMAM (2004) Classification of congenital melanocytic naevi and malignant transformation: a review of the literature. BrJ Plastic Surg 57:707–719

    Article  CAS  Google Scholar 

  • Zeng Q, Si X, Horstmann H, Xu Y, Hong W, Pallen CJ (2000) Prenylation-dependent association of proteintyrosine phosphatases PRL-1,-2, and-3 with the plasma membrane and the early endosome. J Biol Chem 275:21444–21452

    Article  PubMed  CAS  Google Scholar 

  • Zeng Q, Dong J-M, Guo K, Li J, Tan H-X, Koh V, Pallen CJ, Manser E, Hong W (2003) PRL-3 and PRL-1 promote cell migration, invasion, and metastasis. Cancer Res 63:2716–2722

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. The Beatson Institute for Cancer Research, Garscube Estate, Switchback Road, Glasgow, G61 1BD, UK

    Kathryn Graham BSc, MB ChB, MRCP (Clinical Research Fellow, Honorary Specialist Registrar in Clinical Oncology)

  2. The Beatson Institute for Cancer Research, Garscube Estate, Switchback Road, Glasgow, G61 1BD, UK

    Michael F. Olson BSc, PhD (Group Leader)

Authors
  1. Kathryn Graham BSc, MB ChB, MRCP
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Michael F. Olson BSc, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Georg-Speyer-Haus, Institute for Biomedical Research, Paul-Ehrlich-Str. 42-44, 60596, Frankfurt am Main, Germany

    Bernd Groner (Director) (Director)

Rights and permissions

Reprints and permissions

Copyright information

© 2007 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Graham, K., Olson, M.F. (2007). The Ras Signalling Pathway as a Target in Cancer Therapy. In: Groner, B. (eds) Targeted Interference with Signal Transduction Events. Resent Results in Cancer Research, vol 172. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-540-31209-3_8

Download citation

  • DOI: https://doi.org/10.1007/978-3-540-31209-3_8

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-540-31208-6

  • Online ISBN: 978-3-540-31209-3

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation